trade sale via partnership, page-8

Borrowing again from the NYT article by Arlene Weinraub;

"The feared 'patent cliff' for brand-name drugs has caused billion-dollar blockbusters....to lose ground to generic competition, so the pharmaceutical industry has been hunting for innovation among small biotechnology companies."

Its interesting to review the case for peptide drug conjugates. For instance, what is the advantage for Janssen in pursuing its collaboration with Phylogica? Put simply, peptide conjugates can expand the druggable landscape by 10 fold. CPPs have demonstrated the capability to "specifically target the tissue-type of interest [to Janssen] and internalise a payload within the cell," refer announcement 1 July 2013.

Blockbuster drugs - with demonstrated efficacy - could potentially find new intracellular targets by piggybacking! Success for Janssen through its collaboration with Phylogica would be a powerful scientific and medical advance. Everyone else will have to catch up.